Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F19%3A10394151" target="_blank" >RIV/00064165:_____/19:10394151 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/19:00109476 RIV/00216208:11110/19:10394151 RIV/00216208:11130/19:10394151 RIV/00216208:11140/19:10394151 and 5 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=-xiBQTuWF6" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=-xiBQTuWF6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2147/CMAR.S183093" target="_blank" >10.2147/CMAR.S183093</a>
Alternative languages
Result language
angličtina
Original language name
Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
Original language description
Purpose: Although inhibitors of vascular endothelial growth factor and inhibitors of epidermal growth factor receptor (EGFRi) are commonly used for the treatment of metastatic colorectal cancer (mCRC), the optimal sequencing of the agents is currently unclear. Methods: A national registry of targeted therapies was used to analyze baseline characteristics and outcomes of patients with mCRC and wild-type KRAS exon 2 status who received bevacizumab and EGFRi (cetuximab or panitumumab) as a part of first- and second-line treatment in either sequence. Results: The cohort included 490 patients (181 patients treated with first-line EGFRi and second-line bevacizumab and 309 patients treated with first-line bevacizumab and second-line EGFRi). Median overall survival (OS) from the initiation on first-line therapy was similar for patients treated with either sequence, reaching 31.8 (95% CI 27.5-36.1) vs 31.4 months (95% CI 27.8-35.0) for EGFRi -> bevacizumab vs bevacizumab -> EGFRi cohort, respectively. Time from first-line initiation to progression on the second-line therapy [progression-free survival (PFS)] was 21.1 (95% CI 19.3-23.0) vs 19.3 months (95% CI 17.3-21.3) for bevacizumab -> EGFRi vs EGFRi -> bevacizumab cohort, respectively (P=0.016). Conclusion: This retrospective analysis of real-world data of patients with wild-type KRAS exon 2 mCRC showed no differences in OS between cohorts treated with bevacizumab -> EGFRi vs the reverse sequence while combined PFS favored the bevacizumab -> EGFRi sequence.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV15-26535A" target="_blank" >NV15-26535A: The role of genetic variations in microRNA genes and in microRNA binding sites in colorectal cancer in relation to personalized therapy</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Management and Research
ISSN
1179-1322
e-ISSN
—
Volume of the periodical
11
Issue of the periodical within the volume
neuveden
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
359-368
UT code for WoS article
000454529000001
EID of the result in the Scopus database
2-s2.0-85059478345